Ligand Reports First Quarter 2024 Financial Results May 7, 2024 04:00PM
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Feb 27, 2024 07:00AM
Ligand Reports Third Quarter 2023 Financial Results Nov 8, 2023 04:01PM
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Oct 25, 2023 04:05PM
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity Sep 6, 2023 07:03AM
View Older Stories

Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Jul 26, 2023 04:05PM Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 19, 2023 04:05PM Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
May 16, 2023 07:30AM Ligand (LGND) Announces Viking Therapeutics Reports Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809
May 16, 2023 07:30AM Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 16, 2023 07:14AM Viking Therapeutics (VKTX) Phase 2b VOYAGE Study of VK2809 Achieved its Primary Endpoint in NASH
May 16, 2023 07:00AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 4, 2023 04:01PM Ligand Reports First Quarter 2023 Financial Results
Apr 26, 2023 04:05PM Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Apr 20, 2023 04:05PM Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
Apr 11, 2023 04:05PM Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
Mar 28, 2023 07:03AM Viking Therapeutics (VKTX) Announces Initiation of Phase 1 Study of VK2735
Mar 28, 2023 07:03AM Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Mar 28, 2023 06:34AM Viking Therapeutics (VKTX) Reports Results from Phase 1 Trial of VK2735
Mar 28, 2023 06:33AM Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
Mar 7, 2023 04:05PM Viking Therapeutics to Participate at Upcoming Investor Conferences
Feb 8, 2023 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Feb 7, 2023 04:05PM Viking Therapeutics to Present at SVB Securities Global Biopharma Conference
Feb 1, 2023 04:05PM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
Jan 9, 2023 07:05AM Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 8, 2022 04:05PM Viking Therapeutics to Present at Stifel 2022 Healthcare Conference
Oct 26, 2022 04:05PM Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 19, 2022 04:05PM Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
Sep 6, 2022 04:05PM Viking Therapeutics to Participate at Upcoming Investor Conferences
Aug 2, 2022 04:05PM Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Jul 27, 2022 04:05PM Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 20, 2022 04:02PM Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
Jul 19, 2022 07:02AM Viking Therapeutics (VKTX) Announces FDA Lifted Clinical Hold on Phase 1b Trial of VK0214
Jul 19, 2022 07:02AM Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Jul 6, 2022 04:05PM Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
May 16, 2022 04:05PM Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference
Apr 27, 2022 04:08PM Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 20, 2022 04:05PM Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022
Apr 6, 2022 04:05PM Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 8, 2022 04:05PM Viking Therapeutics to Present at Upcoming Investor Conferences
Feb 9, 2022 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Feb 7, 2022 04:05PM Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference
Feb 2, 2022 04:05PM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022
Jan 24, 2022 07:02AM Viking Therapeutics (VKTX) Announces FDA's Clinical Hold on Phase 1b Trial of VK0214
Jan 24, 2022 07:02AM Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Jan 10, 2022 07:02AM Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
Jan 3, 2022 07:30AM Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Nov 9, 2021 04:05PM Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
Nov 3, 2021 04:05PM Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 1, 2021 07:04AM Viking Therapeutics (VKTX) Reports Preclinical Data on Novel Dual GLP-1/GIP Agonists
Nov 1, 2021 07:03AM Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021
Oct 27, 2021 04:05PM Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021
Oct 25, 2021 07:05AM Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Oct 5, 2021 04:05PM Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
Sep 2, 2021 04:05PM Viking Therapeutics to Participate in Upcoming Investor Conferences
View Older Stories